BioSpace News Archive

BMS’ CAR-T therapy Breyanzi picked up a second approval from the FDA. The cancer drug was approved for the treatment of adult patients with large B-cell lymphoma.

For the exercise-phobic, a pill that would create the benefits of exercise without the work has been a pipe dream. Today, such a pill – actually, an “anti-hunger molecule” – is a bit closer to reality.

Otsuka Pharmaceutical and Lundbeck announced positive Phase III clinical trial results Monday regarding brexpiprazole (Rexulti) as a treatment for agitation in patients with Alzheimer’s dementia.

Monday morning, Nuvation Bio announced that the U.S. Food and Drug Administration placed a partial clinical hold on its Phase I dose escalation study of NUV-422.

Ipsen and Epizyme announced that they have entered into a definitive merger agreement under which Ipsen will acquire Epizyme.

Abcam plc, a global leader in the supply of life science research tools, announces the appointment of Tommy Thomas as Vice President of Investor Relations.

Basilea Pharmaceutica Ltd, a commercial-stage biopharmaceutical company, announced an update on the progress made in the implementation of its strategic focus on anti-infectives.

AbbVie announced the European Medicines Agency’s Committee for Medicinal Products for Human Use recommended the approval of upadacitinib for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated C-reactive protein and/or magnetic resonance imaging, who have responded inadequately to nonsteroidal anti-inflammatory drugs.*

ANGLE plc, a world-leading liquid biopsy company, is delighted to announce ground-breaking research by the world-class team at the Molecular Oncology Laboratory at the Swiss Federal Institute of Technology Zurich, Switzerland.

The COVID-19 pandemic has emphatically and adversely affected the market. Adverse consequences incorporate seriously limited purchasing limit of hospitals, particularly limited scope hospitals and imaging focuses.